The mechanistic target of rapamycin complex 1 (mTORC1) is a master regulator of cell
growth that responds to a diverse set of environmental inputs, including amino acids. Over …

The mechanistic target of rapamycin (mTOR) network is an evolutionary conserved signaling
hub that senses and integrates environmental and intracellular nutrient and growth factor …

Background Registry data on patients with type 1 diabetes mellitus who undergo pancreatic
islet transplantation indicate that only 8 percent are free of the need for insulin therapy at …

Background Immunosuppressive regimens with the fewest possible toxic effects are
desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects …

New onset diabetes is a major complication after kidney transplantation. However, the
incidence, risk factors and clinical relevance of post-transplant diabetes mellitus (PTDM) …

Background Angiomyolipomas in patients with the tuberous sclerosis complex or sporadic
lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis genes …

This article provides a comprehensive, up-to-date review of methods to prevent early and
late renal-allograft loss and to improve long-term outcomes in patients. The authors focus …

Background—Restenosis remains an important limitation of interventional cardiology.
Therefore, we aimed to determine the safety and efficacy of sirolimus (a cell-cycle inhibitor) …

Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the
efficacy and safety outcomes of this treatment after kidney transplant require confirmation …

Background Acute rejection episodes after renal transplantation are an important clinical
challenge, despite use of multidrug immunosuppressive regimens. We did a prospective …